Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Operating Leases (2019 - 2025)

Historic Operating Leases for Niagen Bioscience (NAGE) over the last 7 years, with Q3 2025 value amounting to $3.1 million.

  • Niagen Bioscience's Operating Leases rose 689.66% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 689.66%. This contributed to the annual value of $2.6 million for FY2024, which is 2121.21% down from last year.
  • Niagen Bioscience's Operating Leases amounted to $3.1 million in Q3 2025, which was up 689.66% from $3.3 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Operating Leases high stood at $4.7 million for Q4 2021, and its period low was $1.4 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Leases was $3.5 million (2021), whereas its average is $3.6 million.
  • In the last 5 years, Niagen Bioscience's Operating Leases surged by 22423.18% in 2022 and then plummeted by 2368.42% in 2024.
  • Over the past 5 years, Niagen Bioscience's Operating Leases (Quarter) stood at $4.7 million in 2021, then dropped by 10.64% to $4.2 million in 2022, then fell by 21.43% to $3.3 million in 2023, then fell by 21.21% to $2.6 million in 2024, then grew by 19.23% to $3.1 million in 2025.
  • Its Operating Leases stands at $3.1 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.5 million for Q1 2025.